Corporate profile

Company Name

Trinity Co., Ltd.

Company No

0108-01-018165

Founded

April 2008

Representativ

Ikume Murase

Office

Kojimachi Sunrise 301, 2-2-31 Kojimachi Chiyoda-ku Tokyo, 102-0083, JAPAN

Capital stock

13 million yen

Main bank

MUFG Bank, Ltd.

Main memberships

Osaka Pharmaceutical Manufacturers Association, e-CTD Association

Vision

Guided since our foundation in 2008 by core values of Excellence, Partnership and Results-focus, Trinity Biomed offers sophisticated, innovative and strategic whole spectrum pharmaceutical consulting services. To date, we have provided CMC services for biological drugs (antibody drugs, vaccines, recombinant products, biosimilars), synthetic drugs and generics, among others.

• We facilitate effective, safe and quick supply of our clients’ life-enhancing products to medical professionals and their patients in Japan.
• We also catalyze optimum outcomes in assisting cooperation between industry and academia.
• Trinity’s right-first-time mindset delivers a one-stop service for market entry of our clients’ pharmaceuticals and medical devices, best defined by speed, quality and value.
• The Trinity difference is in attentive, close collaboration from the earliest development stage to prompt, accurate post-submission and post-launch follow-up.

With these solid local strengths, we aim to become the ‘go-to’ consultancy for pharmaceutical and medical device innovators seeking to significantly reduce the anxiety and costs associated with product commercialization in Japan: the world’s second largest market.